Showing results (2541-2550 of 4,554) with videos related to
Sort By:
Pageof 456
Journal of Gastroenterology|October 18, 2018
Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trialRenate Schmelz, Stephan Miehlke, Christian Thiede, et al.Journal of Gastroenterology|August 14, 2018
Epithelial-stromal crosstalk and fibrosis in eosinophilic esophagitisAmanda B Muir, Joshua X Wang, Hiroshi NakagawaJournal of Gastroenterology|July 5, 2018
A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer riskDongying Gu, Shuwei Li, Mulong Du, et al.Journal of Gastroenterology|October 1, 2021
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogsDaiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, et al.Journal of Gastroenterology|July 11, 2022
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysisQunfang Zhou, Xiaohui Wang, Ruixia Li, et al.Journal of Gastroenterology|July 19, 2022
Mortality and cancer in eosinophilic gastrointestinal disorders distal to the esophagus: nationwide cohort study 1990-2017Adam C Bledsoe, John J Garber, Weimin Ye, et al.Journal of Gastroenterology|June 27, 2019
A novel urinary microRNA biomarker panel for detecting gastric cancerHiroyasu Iwasaki, Takaya Shimura, Tamaki Yamada, et al.Journal of Gastroenterology|February 13, 2022
Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resectionXiao-Hui Wang, Zi-Li Hu, Yi-Zhen Fu, et al.Journal of Gastroenterology|March 31, 2022
Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 yearsYutaka Suzuki, Toshiyuki Mori, Hirokazu Momose, et al.Journal of Gastroenterology|September 24, 2018
Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory typeYutaka Nagata, Motohiro Esaki, Tomohiko Moriyama, et al.Pageof 456